674,096 Shares in Astera Labs, Inc. $ALAB Bought by Deutsche Bank AG

Deutsche Bank AG bought a new position in Astera Labs, Inc. (NASDAQ:ALAB) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 674,096 shares of the company’s stock, valued at approximately $325,602,000.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Astera Labs by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 13,827,506 shares of the company’s stock worth $2,300,344,000 after purchasing an additional 84,365 shares during the last quarter. Atreides Management LP boosted its holdings in shares of Astera Labs by 108.9% in the 1st quarter. Atreides Management LP now owns 3,365,787 shares of the company’s stock worth $368,890,000 after buying an additional 1,754,593 shares during the last quarter. State Street Corp boosted its stake in Astera Labs by 32.5% in the fourth quarter. State Street Corp now owns 3,099,809 shares of the company’s stock valued at $515,684,000 after acquiring an additional 760,358 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Astera Labs by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 2,429,078 shares of the company’s stock valued at $403,598,000 after acquiring an additional 104,935 shares during the period. Finally, Fred Alger Management LLC increased its stake in shares of Astera Labs by 25.5% during the 4th quarter. Fred Alger Management LLC now owns 1,934,688 shares of the company’s stock worth $321,855,000 after purchasing an additional 393,250 shares during the last quarter. 60.47% of the stock is owned by institutional investors.

Insider Activity at Astera Labs

In other news, Director Stefan A. Dyckerhoff sold 8,994 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $364.35, for a total value of $3,276,963.90. Following the completion of the sale, the director directly owned 5,292 shares of the company’s stock, valued at approximately $1,928,140.20. This trade represents a 62.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Manuel Alba sold 136,974 shares of Astera Labs stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $442.01, for a total transaction of $60,543,877.74. Following the sale, the director directly owned 1,287,524 shares in the company, valued at $569,098,483.24. The trade was a 9.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 631,979 shares of company stock valued at $215,479,247 in the last 90 days. 10.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. UBS Group restated a “neutral” rating and issued a $425.00 price objective on shares of Astera Labs in a research note on Wednesday, August 5th. Needham & Company LLC increased their price objective on Astera Labs from $260.00 to $425.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Barclays raised their target price on shares of Astera Labs from $200.00 to $325.00 and gave the company an “equal weight” rating in a research note on Monday, July 20th. Bank of America raised their price target on Astera Labs from $240.00 to $450.00 and gave the company a “neutral” rating in a research report on Tuesday, June 23rd. Finally, TD Cowen lowered their price objective on shares of Astera Labs from $425.00 to $375.00 and set a “hold” rating for the company in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Astera Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.00.

Astera Labs Price Performance

Shares of NASDAQ:ALAB opened at $320.17 on Tuesday. The stock’s 50-day moving average is $357.48 and its 200 day moving average is $241.79. The company has a market cap of $55.55 billion, a PE ratio of 158.50 and a beta of 3.84. Astera Labs, Inc. has a 1 year low of $97.89 and a 1 year high of $499.48.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.11. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%.The business had revenue of $392.40 million during the quarter, compared to analysts’ expectations of $360.85 million. During the same quarter last year, the business posted $0.44 EPS. The business’s revenue was up 104.5% on a year-over-year basis. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Analysts expect that Astera Labs, Inc. will post 2.7 EPS for the current fiscal year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.